PATIAS INNOVATION AS
Operating
Eierskap i selskaper og forskning innen medisin, spesielt rettet mot
selskaper som har til formål å utvikle adjuvanter innen
resistensproblematikk. I tillegg har selskapet som formål å utøve
konsulentvirksomhet.
Skal arbeide med forskning, utvikling, markedsføring og salg av nye
hjelpestoffer (adjuvanter) som motvirker antibiotikaresistens, slik at
kjente antibiotika virker bedre. Selskapet skal også arbeide med nye
teknologier mot virus-pandemier. Selskapet skal også brukes til å være
passiv og aktiv eier i slike selskaper samt å utøve
konsulentvirksomhet.
Organization
- CEO
- PR
Pål Rongved1953
- Chairman of the board
- PR
Pål Rongved1953
- Years since formation
- 6 years
- since Jun 16, 2020
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 30,000
- 1 share class
- Total number of shareholders
- 1
- person
Financials
- Annual total result 2025
- 18,734
- NOK
- Total equity 2025
- 13,172,851
- NOK
Last update: Jun 6, 2026
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
PR 1953 | Managing Director/CEO | 100 % directly |
Board
| Name | Role | Shares |
|---|---|---|
PR 1953 | Chairman | 100 % directly |
| Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
PR 1953 | Managing Director/CEO, Chairman | 100 % directly |
Last update: Oct 16, 2024
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
PR 1953 | Ordinary shares | 30,000 | 100 % |
Shares owned by the PATIAS INNOVATION AS
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 22,715 | 46.27 % |
Last update: Jun 2, 2025
Financials
in NOK
Summary
| Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
Total operating income | 0 | 722,480 | 0 | 188,500 |
Annual Total Result | 18,734 | 1,285,070 | 296,690 | 3,991,243 |
Total assets | 13,179,251 | 13,449,717 | 12,244,663 | 12,115,588 |
Total liabilities | 6,400 | 295,601 | 105,616 | 153,232 |
Total equity | 13,172,851 | 13,154,117 | 12,139,047 | 11,962,356 |
P&L
| Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
Total operating income | 0 | 722,480 | 0 | 188,500 |
Total operating costs | 30,430 | 117,757 | 55,933 | 20,900 |
Operating result | -30,430 | 604,723 | -55,933 | 167,600 |
Financial income/costs | 55,564 | 873,920 | 436,540 | 3,905,586 |
Profit before tax | 25,134 | 1,478,643 | 380,607 | 4,073,186 |
Total tax & extraordinary income/cost | 6,400 | 193,573 | 83,917 | 81,943 |
Annual Total Result | 18,734 | 1,285,070 | 296,690 | 3,991,243 |
Balance overview
| Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
Total fixed assets | 13,133,843 | 12,699,391 | 12,192,229 | 11,848,740 |
Total current assets | 45,408 | 750,326 | 52,434 | 266,848 |
Total assets | 13,179,251 | 13,449,717 | 12,244,663 | 12,115,588 |
Short term debt | 6,400 | 295,601 | 105,616 | 153,232 |
Long term debt | 0 | 0 | 0 | 0 |
Total liabilities | 6,400 | 295,601 | 105,616 | 153,232 |
Contributed capital | 30,000 | 30,000 | 30,000 | 30,000 |
Retained earnings | 13,142,851 | 13,124,117 | 12,109,047 | 11,932,356 |
Total equity | 13,172,851 | 13,154,117 | 12,139,047 | 11,962,356 |
Total equity and liabilities | 13,179,251 | 13,449,717 | 12,244,663 | 12,115,588 |
Classification
21st company classification
BETA
Small company
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises